MD970254A - Use of melatonine for treatment of patients having a medicamental dependence - Google Patents
Use of melatonine for treatment of patients having a medicamental dependenceInfo
- Publication number
- MD970254A MD970254A MD97-0254A MD970254A MD970254A MD 970254 A MD970254 A MD 970254A MD 970254 A MD970254 A MD 970254A MD 970254 A MD970254 A MD 970254A
- Authority
- MD
- Moldova
- Prior art keywords
- dependence
- melatonine
- patients
- treatment
- medicamental
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to the use of melatonine for treatment of patients having polymedi-camental dependence, patient having symptoms of benzodiasepine drug tolerance or dependence, or patie
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/381,535 US6469044B1 (en) | 1995-02-01 | 1995-02-01 | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
EP95303853A EP0724878B1 (en) | 1995-02-01 | 1995-06-06 | Use of melatonin for treating patients suffering from drug dependencies |
PCT/IB1996/000082 WO1996023496A1 (en) | 1995-02-01 | 1996-01-29 | Use of melatonin for treating patients suffering from drug addiction |
Publications (3)
Publication Number | Publication Date |
---|---|
MD970254A true MD970254A (en) | 1999-05-31 |
MD1716B2 MD1716B2 (en) | 2001-08-31 |
MD1716C2 MD1716C2 (en) | 2002-02-28 |
Family
ID=26140195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MD97-0254A MD1716C2 (en) | 1995-02-01 | 1996-01-29 | Use of melatonin for treatment of patients dependent on benzodiazepine |
Country Status (22)
Country | Link |
---|---|
JP (1) | JP4516159B2 (en) |
CN (1) | CN1083263C (en) |
AT (1) | AT408188B (en) |
AU (1) | AU695366B2 (en) |
BG (1) | BG62876B1 (en) |
BR (1) | BR9607169A (en) |
CZ (1) | CZ291349B6 (en) |
DK (1) | DK176081B1 (en) |
EE (1) | EE03384B1 (en) |
FI (1) | FI119586B (en) |
IS (1) | IS1980B (en) |
LU (1) | LU90118B1 (en) |
LV (1) | LV11940B (en) |
MD (1) | MD1716C2 (en) |
NO (1) | NO312814B1 (en) |
NZ (1) | NZ298878A (en) |
PL (1) | PL183148B1 (en) |
SI (1) | SI9620022A (en) |
SK (1) | SK284521B6 (en) |
TR (1) | TR199700723T1 (en) |
TW (1) | TW483757B (en) |
WO (1) | WO1996023496A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK287508B6 (en) | 2000-01-05 | 2010-12-07 | Neurim Pharmaceuticals (1991) Ltd. | Use and formulation for treating resistance to antihypertensives and related conditions |
IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
KR20180100450A (en) | 2012-01-26 | 2018-09-10 | 반다 파마슈티칼즈, 인코퍼레이티드. | Treatment of circadian rhythm disorders |
US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
KR102148990B1 (en) | 2012-12-18 | 2020-08-27 | 반다 파마슈티칼즈, 인코퍼레이티드. | Treatment of circadian rhythm disorders |
US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
SI3337462T1 (en) * | 2016-10-31 | 2021-01-29 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0518468B1 (en) * | 1991-05-09 | 1999-06-30 | Neurim Pharmaceuticals (1991) Limited | Melatonin containing compositions |
IT1251544B (en) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE |
-
1996
- 1996-01-29 CZ CZ19972405A patent/CZ291349B6/en not_active IP Right Cessation
- 1996-01-29 WO PCT/IB1996/000082 patent/WO1996023496A1/en active IP Right Grant
- 1996-01-29 AU AU44574/96A patent/AU695366B2/en not_active Expired
- 1996-01-29 PL PL96321630A patent/PL183148B1/en unknown
- 1996-01-29 MD MD97-0254A patent/MD1716C2/en not_active IP Right Cessation
- 1996-01-29 SI SI9620022A patent/SI9620022A/en not_active IP Right Cessation
- 1996-01-29 TR TR97/00723T patent/TR199700723T1/en unknown
- 1996-01-29 SK SK1030-97A patent/SK284521B6/en unknown
- 1996-01-29 NZ NZ298878A patent/NZ298878A/en not_active IP Right Cessation
- 1996-01-29 BR BR9607169A patent/BR9607169A/en not_active Application Discontinuation
- 1996-01-29 JP JP52338596A patent/JP4516159B2/en not_active Expired - Lifetime
- 1996-01-29 CN CN96191750A patent/CN1083263C/en not_active Expired - Lifetime
- 1996-01-29 AT AT0901396A patent/AT408188B/en not_active IP Right Cessation
- 1996-01-29 EE EE9700166A patent/EE03384B1/en not_active IP Right Cessation
- 1996-04-12 TW TW085104319A patent/TW483757B/en not_active IP Right Cessation
-
1997
- 1997-07-24 LV LVP-97-144A patent/LV11940B/en unknown
- 1997-07-25 IS IS4532A patent/IS1980B/en unknown
- 1997-07-30 BG BG101803A patent/BG62876B1/en unknown
- 1997-07-30 DK DK199700896A patent/DK176081B1/en not_active IP Right Cessation
- 1997-07-31 NO NO19973531A patent/NO312814B1/en not_active IP Right Cessation
- 1997-07-31 FI FI973185A patent/FI119586B/en not_active IP Right Cessation
- 1997-08-01 LU LU90118A patent/LU90118B1/en active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9700603A1 (en) | Pharmaceutical preparation for the treatment of blood coagulation disorders | |
ES2165910T3 (en) | NASAL AND OCULAR CETAMINE ADMINISTRATION FOR THE TREATMENT OF PAIN AND FOR DETOXIFICATION. | |
BG101118A (en) | Therapeutical compounds | |
NO20101190L (en) | Use of buprenorphine in the manufacture of a medicament | |
IL127714A0 (en) | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic depressive bipolar disorders | |
AU677279B2 (en) | Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes | |
HUT77927A (en) | Use of nebivolol for producing anti-atherogenic pharmaceuticals and combination pharmaceuticals containing them | |
PT998287E (en) | USES OF LEVOBUPIVACAINE | |
AU4024797A (en) | Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia | |
HUP0001014A2 (en) | Use of gastrointestinal lipase inhibitors | |
ES2160643T3 (en) | COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF. | |
MD970254A (en) | Use of melatonine for treatment of patients having a medicamental dependence | |
GB0020504D0 (en) | Therapeutic method | |
AU2001261987A1 (en) | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders | |
AU2787495A (en) | Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis | |
MX9803610A (en) | Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system. | |
IT1288399B1 (en) | MEDICATION FOR THE THERAPEUTIC TREATMENT OF AGE-RELATED MACULOPATHY, NON-AGE-RELATED MACULOPATHY AND FOR PROPHYLAXIS | |
NO990450L (en) | Treatment of mental disorders | |
AU7718796A (en) | 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus | |
TW330933B (en) | Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes | |
NO984651L (en) | Use of benzone-offset derivatives for the manufacture of drugs for the treatment of central nervous system diseases | |
AU5434899A (en) | Cancer treatment | |
AU5890499A (en) | Use of composition in the treatment of schizophrenia | |
UA22223A (en) | Method for treatment of vision organ diseases | |
UA30361A (en) | The method for treatment of glycoside intoxication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD99 | Pending application | ||
KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
MM4A | Patent for invention definitely lapsed due to non-payment of fees |